DeMuth Peter 4

4 · Elicio Therapeutics, Inc. · Filed Feb 3, 2026

AI-generated summary of this filing

Updated Feb 3, 2026

Elicio (ELTX) CSO Peter DeMuth Receives RSU and Option Awards

What Happened

Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, was granted 20,800 restricted stock units (RSUs) and 41,600 stock options (reported as a derivative grant) on February 2, 2026. Both awards were reported at $0.00 (no cash paid at grant). Each RSU represents the right to receive one share of common stock upon vesting.

Key Details

Transaction date: 2026-02-02; Form 4 filed 2026-02-03 (filed timely, within one business day).
Transaction code: "A" = award/grant.
RSUs: 20,800 RSUs; acquisition price $0.00. Vesting (F1): 25% on Feb 2, 2027, then annual installments over the next three years, subject to continued service.
Options (derivative): 41,600 options; reported as acquired at $0.00. Vesting (F2): 25% on Feb 2, 2027, then monthly vesting over the following three years, subject to continued service.
Post-transaction holdings: Not specified in the provided filing.
No immediate sale or purchase — these are time‑based compensation awards, not open-market trades.

Context

These awards are time‑vested compensation; they do not represent an immediate transfer of shares to the insider and require continued service to vest.
Reporting of $0.00 reflects grant status (no cash outlay at grant). The filing does not indicate exercise, sale, tax-withholding, or a 10b5-1 plan.

Form 4

Period: 2026-02-02

Chief Scientific Officer

Transactions

Award
Common Stock
[F1]
2026-02-02+20,800→ 21,543 total
Award
Stock Option (Right to Buy)
[F2]
2026-02-02+41,600→ 41,600 total
Exercise: $8.10Exp: 2036-02-02→ Common Stock (41,600 underlying)

Footnotes (2)

[F1]Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer.
[F2]The stock option vests and becomes exercisable as to 25% of the options on February 2, 2027, the first anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Signature

/s/ Peter DeMuth|2026-02-03

1 file